- HEALTH INFORMATION
- GET SUPPORT
- NEWS & VIEWS
- GET INVOLVED
- CARE PROVIDERS
The next generation of patient education brochures are now available. This new literature has several improvements and we hope you find them as exciting as we do. The brochures topics include preeclampsia, HELLP syndrome and heart disease and were updated to make them more readable, attractive, and, most importantly, to offer a variety of new information.
Preeclampsia (English and Spanish) - What is it? What causes it? Who will get it? How can it be prevented? What are the signs and symptoms? What can I expect if I get it? Where can I find answers to some of the basic questions about preeclampsia? The FAQ brochure provides the invaluable answers. Updates to this piece include new statistics, inclusion of more risk factors for preeclampsia, and a constant reminder to "Know the symptoms. Trust yourself."
Preeclampsia & Heart Disease - Did you know women who have preeclampsia have double the risk for heart disease and stroke over their next five to 15 years? This brochure has a considerable amount of new information including helpful ways to reduce the risk of heart disease and the importance of sharing your pregnancy history with all your health care providers.
HELLP Syndrome - In 2009, the HELLP Syndrome Society merged with the Preeclampsia Foundation. This brochure, an important new addition to the Preeclampsia Foundation's collection of patient literature, explains this severe variant of preeclampsia.
"Information is life-saving!" says Executive Director Eleni Tsigas. "When a patient knows the signs and symptoms of preeclampsia and understands the importance of reporting her concerns, she stands a much better chance of improving her and her baby's outcome and avoiding a 'crisis' delivery."
Doctors' offices and clinics may be interested in another new feature: for a fee, all brochures can be customized with a local address, phone number or other information. All brochures - generic and customizable - can be ordered via our Marketplace.